allows blood bank customers to automate applications in their
manufacturing and distribution operations
-- Acquisition of the TEG(R) Thrombelastograph(R) Hemostasis Analyzer
business which is expected to add more than $16 million in annual
-- Acquisition of Infonale which gives Haemonetics strategic expertise in
hospital blood management consulting services
-- Restructuring of European and Asian operations which reported revenue
growth of 11% and 19%, respectively
-- Completion of Phase I of an enterprise resource planning initiative
which converted all geographies, sales, service and financial functions
to a new system
ANNUAL PRODUCT LINE GROWTH
Among the product lines, plasma disposables revenue was $40 million for the quarter, up 32%. Annual plasma disposables revenue was $155 million, up 22%. Plasma disposable sales benefited from continued growth in U.S. and European plasma collections as well as from Haemonetics' collection growth at new customer sites. Haemonetics expects that growth in the plasma market will continue to drive strong plasma sales for the next several years.
Blood bank disposables revenue was $36 million for the quarter, up 11%. Annual blood bank disposables revenue was $136 million, up 8%. Blood bank growth was driven by strong sales in Europe and Asia as the Company sees early benefits from last year's reorganization initiatives.
Red cell disposables revenue was $12 million for the quarter, up 7%. Annual red cell disposables revenue was $46 million, up 7%. Strong equipment sales of the newest generation Cymbal(R) automated blood collection system and the MCS(R)+ mobile collection system in the first half of the year drove strong product line sales. Including equipment, total revenues for the red cell product line grew 13% in the year.
|SOURCE Haemonetics Corporation|
Copyright©2008 PR Newswire.
All rights reserved